AscentX Medical, Inc.

San Diego, CA · Founded 2017 · CIK 0001720591 · Biotech · Private

Injectable regenerative therapies using advanced soft tissue engineering

ascentxmedical.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$3.3M
4 Form D · Aug 2023
38 months since last filing
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$1,220,156
Private capital raisedForm D · SEC$324,968
Private capital raisedForm D · SEC$1,178,320
Private capital raisedForm D · SEC$557,610
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1685CORE BIOTHERAPEUTICS INC——
1686HUMAN CELL CO——
1687SYMBIOTIX BIOTHERAPIES, INC.——
1688AscentX Medical, Inc.—$3.3M
1689Revolve Biotechnologies, Inc.——
1690MPEX PHARMACEUTICALS, INC.——
1691iQure Pharma Inc.—$5.3M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 9 related persons
  • Larry BragaDirector · Executive Officer
  • David FrisciaDirector
  • Glen LehmanDirector
  • Gottfried LemperleDirector
  • Stefan LemperleDirector · Executive Officer
  • John LynchDirector
  • Juergen SiemonsmeirDirector
  • John StiskaDirector
  • Yibo WangDirector

Patents

USPTO · 0 granted of 2
  • Compositions And Methods Of Suspended Hyaluronic Acid Microspheres For Tissue And Skin Regeneration, Augmentation, Repair, And Adjustmentapplication
  • Injection Apparatus For Long Distance Delivery Of Soft Tissue Bulking Agents Contaning Microspheresapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.